Hundreds of people with Attention Deficit Hyperactivity Disorder (ADHD) in Cyprus face the risk of serious deterioration in their condition due to prolonged shortages of both pharmaceutical treatments available on the island.
The situation has raised significant concern among psychiatrists, psychologists, the Ministry of Health and the Health Insurance Organisation, prompting a high-level meeting yesterday aimed at finding solutions to the crisis.
“When a person with ADHD cannot consistently receive their medication, they begin to develop problems which, in some cases, put them at risk,” Marina Georgiou, president of the ADHD Association, told philenews.
“A child who doesn’t receive their medication may become aggressive, while an adult with reduced concentration might, for example, cause an accident on the road,” she added.
The two specific medications (Concerta and Atomoxetine in various strengths) “have frequently been in short supply over the past three years,” Georgiou said. “The current shortage has persisted since late 2024, and we’ve been informed that only small stocks are expected in the coming period”.
Relevant departments of the Ministry of Health, including the Directorate of Purchases and Supplies and the Pharmaceutical Services, are working to secure sufficient quantities to cover all patients requiring these medications, according to Georgiou.
“We’ve been informed that the shortage is due to insufficient stock from manufacturers, which has also affected exports from some EU countries. In Cyprus, we’re expecting around 700 packages of each of the two medications to arrive, and this quantity may or may not be enough to cover the needs of people with ADHD for one month,” she explained.
During yesterday’s meeting, officials decided to pursue authorisation for alternative formulations used in other countries while intensifying efforts “to import larger quantities of the two medications as soon as possible”.
A deadline of March 21 has been set for all stakeholders to reconvene and determine next steps to address the growing shortfall.
“Medication is a fundamental pillar in managing ADHD, directly affecting individuals’ functionality, whether in education for children, or in work, social life, and daily activities for adults,” Georgiou emphasised.
“The prolonged shortage of these specific medications simultaneously causes a serious impact on the health and quality of life of people with ADHD, with potential negative consequences for their interpersonal relationships,” she concluded.
